Increased arthritis susceptibility in cartilage proteoglycan-specific T cell receptor-transgenic mice

Arthritis and Rheumatism

Volumn 54, Issue 8, 2006, Pages 2423-2433

  Berlo, Suzanne E ^a   Guichelaar, Teun ^a   Ten Brink, Corlinda B ^a   Van Kooten, Peter J ^a   Hauet Broeren, Femke ^a   Ludanyi, Katalin ^b   Van Eden, Willem ^a   Broeren, Chris P ^c   Glant, Tibor T ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c Rush University Medical Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; PROTEOGLYCAN; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYARTHRITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCID MOUSE; SPLEEN CELL; T LYMPHOCYTE; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; AGGRECANS; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CARTILAGE; CELL TRANSPLANTATION; EPITOPES, T-LYMPHOCYTE; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INBREEDING; LECTINS, C-TYPE; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; MICE, TRANSGENIC; PROTEOCHONDROITIN SULFATES; RECEPTORS, ANTIGEN, T-CELL; SPLEEN; T-LYMPHOCYTES;

EID: 33746983501     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22013     Document Type: Article

References (50)

1. Goronzy JJ, Weyand CM. Rheumatoid arthritis. Immunol Rev 2005;204:55-73.
2. Klareskog L, McDevitt H. Rheumatoid arthritis and its animal models: the role of TNF-α and the possible absence of specific immune reactions. Cirr Opin Immunol 1999;11:657-62.
3. Weyand CM, Goronzy JJ, Takemura S, Kurtin PJ. Cell-cell interactions in synovits. Interactions between T cells and B cells in rheumatoid arthritis. Arthritis Res 2000;2:457-63.
4. Dolhain RJ, van der Heiden AN, ter Haar NT, Breedveld FC, Miltenburg AM. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1961-9.
5. Van der Graaff WL, Prins AP, Dijkmans BA, van Lier RA. Prognostic value of Th1/Th2 ratio in rheumatoid arthritis [letter]. Lancet 1998;351:1931.
6. Van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002;4:87-93.
7. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
8. Dumont FJ. Technology evaluation: abatacept, Bristol-Myers Squibb. Curr Opin Mol Ther 2004;6:318-30.
9. Glant T, Csongor J, Szucs T. Immunopathologic role of proteoglycan antigens in rheumatoid joint diseases. Scand J Immunol 1980;11:247-52.
10. Golds EE, Stephen IBM, Esdaile JM, Strawczynski H, Poole AR. Lymphocyte transformation to connective tissue antigens in adult and juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus and a non-arthritic control population. Cell Immunol 1983;82:196-209.
11. Goodstone NJ, Doran MC, Hobbs RN, Butler RC, Dixey JJ, Ashton BA. Cellular immunity to cartilage aggrecan core protein in patients with rheumatoid arthritis and non-arthritic controls. Ann Rheum Dis 1996;55:40-6.
12. Guerassimov A, Zhang Y, Banerjee S, Cartman A, Leroux JY, Rosenberg LC, et al. Cellular immunity to the G1 domain of cartilage proteoglycan aggrecan is enhanced in patients with rheumatoid arthritis out only after removal of keratan sulfate. Arthritis Rheum 1998;41:1019-25.
13. Li NL, Zhang DQ, Zhou KY, Cartman A, Leroux JY, Poole AR, et al. Isolation and characteristics of autoreactive T cells specific to aggrecan G1 domain from rheumatoid arthritis patients. Cell Res 2000;10:39-49.
14. Zou J, Zhang Y, Thiel A, Rudwaleit M, Shi SL, Radbruch A, et al. Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. Rheumatology (Oxford) 2003;42:846-55.
15. Rosenberg LC, Buckwalter JA. Cartilage proteoglycans. In: Kuettner KE, Schleyerbach R, Hascall VC, editors. Articular cartilage biochemistry. New York: Raven Press; 1986. p. 39-57.
16. Glant TT, Buzas EI, Finnegan A, Negroiu G, Cs-Szabo G, Mikecz K. Critical role of glycosaminoglycan side chains of cartilage proteoglycan (aggrecan) in antigen recognition and presentation. J Immunol 1998;160:3812-9.
17. Poole AR, Ionescu M, Swan A, Dieppe PA. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan: implications for pathogenesis. J Clin Invest 1994;94:25-33.
18. Glant TT, Mikecz K, Arzoumanian A, Poole AR. Proteoglycan-induced arthritis in BALB/c mice: clinical features and histopathology. Arthritis Rheum 1987;30:201-12.
19. Hanyecz A, Berlo SE, Szanto S, Broeren CPM, Mikecz K, Glant TT. Achievement of a synergistic adjuvant effect on arthritis induction by activation of innate immunity and forcing the immune response toward the Th1 phenotype. Arthritis Rheum 2004;50:1665-76.
20. Glant TT, Finnegan A, Mikecz K. Proteoglycan-induced arthritis: immune regulation, cellular mechanisms and genetics. Crit Rev Immunol 2003;23:199-250.
21. Glant TT, Mikecz K. Proteoglycan aggrecan-induced arthritis: a murine autoimmune model of rheumatoid arthritis. Methods Mol Med 2004;102:313-38.
22. Mikecz K, Glant TT. Migration and homing of lymphocytes to lymphoid and synovial tissues in proteoglycan-induced murine arthritis. Arthritis Rheum 1994;37:1395-403.
23. Gal I, Bajnok E, Szanto S, Sarraj B, Glant TT, Mikecz K. Visualization and in situ analysis of leukocyte trafficking into the ankle joint in a systemic murine model of rheumatoid arthritis. Arthritis Rheum 2005;52:3269-78.
24. Buzas E, Mikecz K, Brennan FR, Glant TT. Mediators of autopathogenic effector cells in proteoglycan-induced arthritic and clinically asymptomatic BALB/c mice. Cell Immunol 1994;158: 292-304.
25. Zhang Y, Guerassimov A, Leroux JY, Cartman A, Webber C, Lalic R, et al. Arthritis induced by proteoglycan aggrecan G1 domain in BALB/c mice: evidence for T cell involvement and the immunosuppressive influence of keratan sulfate on recognition of T and B cell epitopes. J Clin Invest 1998;101:1678-86.
26. Banerjee S, Webber C, Poole AR. The induction of arthritis in mice by the cartilage proteoglycan aggrecan: roles of CD4+ and CD8+ T cells. Cell Immunol 1992;144:347-57.
27. Mikecz K, Glant TT, Buzas E, Poole AR. Proteoglycan-induced polyarthritis and spondylitis adoptively transferred to naive (nonimmunized) BALB/c mice. Arthritis Rheum 1990;33:866-76.
28. Bardos T, Mikecz K, Finnegan A, Zhang J, Glant TT. T and B cell recovery in arthritis adoptively transferred to SCID mice: antigen-specific activation is required for restoration of autopathogenic CD4+ Th1 cells in a syngeneic system. J Immunol 2002;168: 6013-21.
29. Buzas EI, Brennan FR, Mikecz K, Garzo M, Negroiu G, Hollo K, et al. A proteoglycan (aggrecan)-specific T cell hybridoma induces arthritis in BALB/c mice. J Immunol 1995;155:2679-87.
30. Zhang J, Bardos T, Mikecz K, Finnegan A, Glant TT. Impaired Fas signaling pathway is involved in defective T cell apoptosis in autoimmune arthritis. J Immunol 2001;166:4981-6.
31. Finnegan A, Mikecz K, Tao P, Glant TT. Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines. J Immunol 1999;163:5383-90.
32. Finnegan A, Grusby MJ, Kaplan CD, O'Neill SK, Eibel H, Koreny T, et al. IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. J Immunol 2002;169: 3345-52.
33. Kouskoff V, Signorelli K, Benoist C, Mathis D. Cassette vectors directing expression of T cell receptor genes in transgenic mice. J Immunol Methods 1995;180:273-80.
34. Szanto S, Bardos T, Szabo Z, David CS, Buzas EI, Mikecz K, et al. Induction of arthritis in HLA-DR4-humanized and HLA-DQ8-humanized mice by human cartilage proteoglycan aggrecan but only in the presence of an appropriate (non-MHC) genetic background. Arthritis Rheum 2004;50:1984-95.
35. Zhang J, Mikecz K, Glant TT, Finnegan A. Spontaneous thymocyte apoptosis is regulated by mitochondrion-mediated signaling pathway. J Immunol 2000;165:2970-4.
36. Carson RT, Vignali DA. Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. J Immunol Methods 1999;227:41-52.
37. Mori L, Loetscher H, Kakimoto K, Bluethmann H, Steinmetz M. Expression of a transgenic T cell receptor β chain enhances collagen-induced arthritis. J Exp Med 1992;176:381-8.
38. Osman GE, Cheunsuk S, Allen SE, Chi E, Liggitt HD, Hood LE, et al. Expression of a type II collagen-specific TCR transgene accelerates the onset of arthritis in mice. Int Immunol 1998;10: 1613-22.
39. Brand DD, Myers LK, Whittington KB, Latham KA, Stuart JM, Kang AH, et al. Detection of early changes in autoimmune T cell phenotype and function following intravenous administration of type II collagen in a TCR-transgenic model. J Immunol 2002;168: 490-8.
40. Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell 1993;72: 551-60.
41. O'Neill SK, Shlomchik MJ, Glant TT, Cao Y, Doodes PD, Finnegan A. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J Immunol 2005;174:3781-8.
42. Hollo K, Glant TT, Garzo M, Finnegan A, Mikecz K, Buzas EI. Complex pattern of Th1 and Th2 activation with a preferential increase of autoreactive Th1 cells in BALB/c mice with proteoglycan (aggrecan)-induced arthritis. Clin Exp Immunol 2000;120: 167-73.
43. Kaplan CD, O'Neill SK, Koreny T, Czipri M, Finnegan A. Development of inflammation in proteoglycan-induced arthritis is dependent on FcγR regulation of the cytokine/chemokine environment. J Immunol 2002;169:5851-9.
44. Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW. Mononuclear phagocytes and rheumatoid synovitis: mastermind or workhorse in arthritis? [review]. Arthritis Rheum 1997;40:5-18.
45. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives [review]. Arthritis Rheum 1997;40:598-609.
46. Pope RM. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2002;2:527-35.
47. Peng SL. Fas (CD95)-related apoptosis and rheumatoid arthritis. Rheumatology (Oxford) 2006;45:26-30.
48. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005;435:590-7.
49. Kronenberg M, Rudensky A. Regulation of immunity by self-reactive T cells. Nature 2005;435:598-604.
50. Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 2005;435:612-9.